Next Phase Newsletter

The venture firm is based in the US, managing a corporate venture fund for a major insurance company. The firm looks to invest in companies of strategic interest to its insurance company LP while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the fund looks to invest in sectors of Healthcare IT, Services, Diagnostics, and Devices.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The company is a health-focused vision care company committed to cultivating the eye health start-up ecosystem. The firm has five business units in ophthalmic innovation, eyewear, lenses, insurance, and practice management. With nearly 90 million members and 30,000 eye care professionals in network, the company’s reach is unprecedented. The firm is looking to invest or partner with companies from seed to revenue stage, investing as early as POC through commercially available products. The firm is interested in technologies from all sectors that are related to eye health (including ocular surface disease, myopia, and glaucoma), or diagnostics or treatments for eye problems caused by other diseases, such as diabetes or neurological diseases. The company will consider seed through late stage investing and partnerships with companies in the US and abroad.

The company will consider all companies associated with vision, ophthalmology, and vision care. This includes all sectors, and could range from new therapeutics to treat glaucoma to digital health technologies to improve vision insurance. VSP Global will also consider technologies treating vision problems that are secondary effects of other indications, such as diabetes.

The firm can lead or co-invest. In addition, the firm will use their network for help with product rollout, if relevant.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A private equity firm based in the USA makes investments for majority or significant minority equity stakes in mature, middle-market companies in the healthcare sector. The firm typically invests $5-20 million in companies valued between $10-100 million. The firm invests in both privately held and publicly traded companies and primarily invests in the USA and Canada.

The firm focuses on healthcare IT, specialty medical devices and products, healthcare services and pharma distribution/supply chain. The firm will consider all opportunities in these fields that match the firm’s financial criteria, and has experience of investing in skincare, enterprise HCIT, hearing devices and wearable devices. The firm only invests in companies with products/services that are on the market and with revenues of at least $5 million per year.

The firm focuses on companies with revenues of $5-75 million, valuations from $10-100 million, and EBITDA from near break-even up to $15 million.  The firm is interested in buyouts, recapitalizations, and opportunities to work alongside founders to scale and improve a company. The firm has the expertise to assist companies in accessing US healthcare markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A financially driven corporate life science venture fund’s purpose is to foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life science companies at various stages of their development, independent form their parent company’s strategy. The firm has offices in USA and Europe, where the firm also focuses its investment activities. The firm has an evergreen structure and currently holds $800 million in assets under management. The firm typically makes equity investments in early venture rounds, investing up to $25 million over multiple financing rounds with 6-8 investments in any given year.

The firm invests in therapeutics with a focus on pre-IND assets and Series A investment rounds. The firm is interested in all classes and indications of innovative therapeutics with paradigm shifting potential.

The firm  invests exclusively in privately held companies and aims to be a lead or co-lead with a director position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early pharma/biotech fund based in Israel is stage-agnostic but fundamentally science-driven and considers mainly early pre-clinical and clinical-stage projects, preferably with POC validation. The firm’s investment size ranges widely from $0.5M – $20M and comes in the form of straight equity. The firm seeks board representation and is a very active investor, helping guide the company’s development and strategy. The firm invests globally and may lead investments, but typically co-invests in U.S.-based companies. The firm has no targeted number of investments per year.

The firm is open to both pre-clinical and clinical stage companies and is agnostic to technology type and indication. The firm has a specific interest in immuno-oncology, gene therapy, RNA/DNA based therapy and orphan or unmet medical need. The firm is only interested in first-in-class, breakthrough assets and does not consider re-purposed assets or iterative technologies.

The firm to invest early and help take the company through a major inflection point. The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm invests in early-stage biotech and pharma companies, mostly investing in seed to Series A rounds while it can also provide later funding (follow-up investment). The firm also seeks to In-licensing and NewCo spinout for later-stage research projects. The firm also has 30,000+ square feet of chemistry/biology incubator space.

The firm mainly looks at biopharmaceutical industry. The firm prefers to work closely with scientific innovators to advance discoveries rapidly through key value-inflection points.

The firm is seeking Seed to pre-IPO research-based U.S. companies developing novel drugs and biologics, with an underlying technology platform.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a VC based in Italy. The firm has just completed the investment period of the third fund and raising their fourth fund, with a target fund size of at least $200M. While their third fund is broader in scope in Life Sciences, the firm’s fourth fund will be focused specifically on therapeutics. Around 50% of their new fund will be dedicated to venture building, and the other half will be dedicated to traditional venture investing. The firm will invest in European and Israeli companies, and will invest from lead identification to IND-stage, although the firm is open to investing in clinical-stage companies. The firm will invest between $5-25M per investment (seed, series A, series B).

The firm is looking to invest only in therapeutics. Within therapeutics, the firm is agnostic to modality. The firm is primarily interested in the indications of oncology (particularly glioblastoma, pancreatic cancer and sarcoma), rare diseases and CNS disorders, particularly those with a genetic origin. The firm is interested in First-In-Class and Best-In-Class therapeutics, but may consider repurposed therapeutics for CNS only.

The firm is interested in investing in experienced management teams. The firm prefers to co-invest, and may take a board seat, but does not require it.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.